Current through Bulletin 2024-18, September 15, 2024
(1) General requirements.
(a) The rule requirements of this section
establish or extend treatment technique requirements in lieu of maximum
contaminant levels for Cryptosporidium. These requirements are in addition to
requirements for filtration and disinfection in R309-200 and other parts of
R309-215.
(b) Applicability. The
requirements of this subpart apply to all surface water systems, which are
public water systems supplied by a surface water source and public water
systems supplied by a ground water source under the direct influence of surface
water.
(i) Wholesale systems, as defined in
R309-110, must comply with the requirements of this section based on the
population of the largest system in the combined distribution system.
(ii) The requirements of this sub-section
apply to systems required by these rules to provide filtration treatment,
whether or not the system is currently operating a filtration system.
(c) Requirements. Systems subject
to this subpart must comply with the following requirements:
(i) Systems must conduct an initial and a
second round of source water monitoring for each plant that treats a surface
water or GWUDI source. This monitoring may include sampling for
Cryptosporidium, E. coli, and turbidity as described in R309-215-15(2) through
R309-215-15(7), to determine what level, if any, of additional Cryptosporidium
treatment they must provide.
(ii)
Systems that plan to make a significant change to their disinfection practice
must develop disinfection profiles and calculate disinfection benchmarks, as
described in R309-215-15(9) through R309-215-15(10).
(iii) Filtered systems must determine their
Cryptosporidium treatment bin classification as described in R309-215-15(11)
and provide additional treatment for Cryptosporidium, if required, as described
in R309-215-15(12). Filtered must implement Cryptosporidium treatment according
to the schedule in
R309-215-14.
(iv) Systems required to provide additional
treatment for Cryptosporidium must implement microbial toolbox options that are
designed and operated as described in R309-215-15(15) through
R309-215-15(20).
(v) Systems must
comply with the applicable recordkeeping and reporting requirements described
in R309-215-15(21) through R309-215-15(22).
(vi) Systems must address significant
deficiencies identified in sanitary surveys performed by EPA as described in
R309-215-15(22).
(2) Source Water Monitoring Requirements.
(a) Initial round of source water monitoring.
Systems must conduct the following monitoring on the schedule in paragraph (c)
of this section unless they meet the monitoring exemption criteria in paragraph
(d) of this section.
(i) Filtered systems
serving at least 10,000 people must sample their source water for
Cryptosporidium, E. coli, and turbidity at least monthly for 24
months.
(ii)
(A) Filtered systems serving fewer than
10,000 people must sample their source water for E. coli at least once every
two weeks for 12 months.
(B) A
filtered system serving fewer than 10,000 people may avoid E. coli monitoring
if the system notifies the Director that it will monitor for Cryptosporidium as
described in paragraph (a)(iv) of this section. The system must notify the
Director no later than 3 months prior to the date the system is otherwise
required to start E. coli monitoring under R309-215-15(2)(c).
(iii) Filtered systems serving
fewer than 10,000 people must sample their source water for Cryptosporidium at
least twice per month for 12 months or at least monthly for 24 months if they
meet one of the following, based on monitoring conducted under paragraph
(a)(iii) of this section:
(A) For systems
using lake/reservoir sources, the annual mean E. coli concentration is greater
than 10 E. coli/ 100 mL.
(B) For
systems using flowing stream sources, the annual mean E. coli concentration is
greater than 50 E. coli/ 100 mL.
(C) The system does not conduct E. coli
monitoring as described in paragraph (a)(iii) of this section.
(D) Systems using ground water under the
direct influence of surface water (GWUDI) must comply with the requirements of
paragraph (a)(iv) of this section based on the E. coli level that applies to
the nearest surface water body. If no surface water body is nearby, the system
must comply based on the requirements that apply to systems using
lake/reservoir sources.
(iv) For filtered systems serving fewer than
10,000 people, the Director may approve monitoring for an indicator other than
E. coli under paragraph (a)(ii) of this section. The Director also may approve
an alternative to the E. coli concentration in paragraph (a)(iii)(A), (B) or
(D) of this section to trigger Cryptosporidium monitoring. This approval by the
Director must be provided to the system in writing and must include the basis
for the Director's determination that the alternative indicator and/or trigger
level will provide a more accurate identification of whether a system will
exceed the Bin 1 Cryptosporidium level in R309-215-15(11).
(v) Systems may sample more frequently than
required under this section if the sampling frequency is evenly spaced
throughout the monitoring period.
(b) Second round of source water monitoring.
Systems must conduct a second round of source water monitoring that meets the
requirements for monitoring parameters, frequency, and duration described in
paragraph (a) of this section, unless they meet the monitoring exemption
criteria in paragraph (d) of this section. Systems must conduct this monitoring
on the schedule in paragraph (c) of this section.
(c) Monitoring schedule. Systems must begin
the monitoring required in paragraphs (a) and (b) of this section no later than
the month beginning with the date listed:
(i)
Systems that serve at least 100,000 people must:
(A) begin the first round of source water
monitoring no later than October 1, 2006; and
(B) begin the second round of source water
monitoring no later than April 1, 2015.
(ii) Systems that serve from 50,000 to 99,999
people must:
(A) begin the first round of
source water monitoring no later than April 1, 2007; and
(B) begin the second round of source water
monitoring no later than October 1, 2015.
(iii) Systems that serve from 10,000 to
49,999 people must:
(A) begin the first round
of source water monitoring no later than April 1, 2008; and
(B) begin the second round of source water
monitoring no later than October 1, 2016.
(iv) Systems that serve less than 10,000
people and monitor for E. coli must:
(A)
begin the first round of source water monitoring no later than October 1, 2008;
and
(B) begin the second round of
source water monitoring no later than October 1, 2017.
(C) Applies only to filtered
systems.
(v) Systems
that serve less than 10,000 people and monitor for Cryptosporidium must:
(A) begin the first round of source water
monitoring no later than April 1, 2010; and
(B) begin the second round of source water
monitoring no later than April 1, 2019.
(C) Applies to filtered systems that meet the
conditions of paragraph (a)(iii) of this section.
(d) Monitoring avoidance.
(i) Filtered systems are not required to
conduct source water monitoring under this sub-section if the system will
provide a total of at least 5.5-log of treatment for Cryptosporidium,
equivalent to meeting the treatment requirements of Bin 4 in
R309-215-15(12).
(ii) If a system
chooses to provide the level of treatment in paragraph (d)(i) of this section
rather than start source monitoring, the system must notify the Director in
writing no later than the date the system is otherwise required to submit a
sampling schedule for monitoring under R309-215-15(3). Alternatively, a system
may choose to stop sampling at any point after it has initiated monitoring if
it notifies the Director in writing that it will provide this level of
treatment. Systems must install and operate technologies to provide this level
of treatment by the applicable compliance dates in R309-215-15(13).
(e) Plants operating only part of
the year. Systems with surface water plants that operate for only part of the
year must conduct source water monitoring in accordance with this subpart, but
with the following modifications:
(i) Systems
must sample their source water only during the months that the plant operates
unless the Director specifies another monitoring period based on plant
operating practices.
(ii) Systems
with plants that operate less than six months per year and that monitor for
Cryptosporidium must collect at least six Cryptosporidium samples per year
during each of two years of monitoring. Samples must be evenly spaced
throughout the period the plant operates.
(f)
(i) New
sources. A system that begins using a new source of surface water or GWUDI
after the system is required to begin monitoring under paragraph (c) of this
section must monitor the new source on a schedule the Director approves. Source
water monitoring must meet the requirements of this sub-section. The system
must also meet the bin classification and Cryptosporidium treatment
requirements of R309-215-15(11) and (12) for the new source on a schedule the
Director approves.
(ii) The
requirements of R309-215-15(2)(f) apply to surface water systems that begin
operation after the monitoring start date applicable to the system's size under
paragraph (c) of this section.
(iii) The system must begin a second round of
source water monitoring no later than 6 years following initial bin
classification under R309-215-15(11).
(g) Failure to collect any source water
sample required under this section in accordance with the sampling schedule,
sampling location, analytical method, approved laboratory, and reporting
requirements of R309-215-15(3) through R309-215-15(7) is a monitoring
violation.
(h) Grandfathering
monitoring data. Systems may use (grandfather) monitoring data collected prior
to the applicable monitoring start date in paragraph (c) of this section to
meet the initial source water monitoring requirements in paragraph (a) of this
section. Grandfathered data may substitute for an equivalent number of months
at the end of the monitoring period. All data submitted under this paragraph
must meet the requirements in R309-215-15(8).
(3) Sampling schedules.
(a) Systems required to conduct source water
monitoring under R309-215-15(2) must submit a sampling schedule that specifies
the calendar dates when the system will collect each required sample.
(i) Systems must submit sampling schedules no
later than 3 months prior to the applicable date listed in R309-215-15(2)(c)
for each round of required monitoring.
(ii)
(A)
Systems serving at least 10,000 people must submit their sampling schedule for
the initial round of source water monitoring under R309-215-15(2)(a) to EPA
electronically at https:// intranet.epa.gov/lt2/.
(B) If a system is unable to submit the
sampling schedule electronically, the system may use an alternative approach
for submitting the sampling schedule that EPA approves.
(iii) Systems serving fewer than 10,000
people must submit their sampling schedules for the initial round of source
water monitoring R309-215-15(2)(a) to the Director.
(iv) Systems must submit sampling schedules
for the second round of source water monitoring R309-215-15(2)(b) to the
Director.
(v) If EPA or the
Director does not respond to a system regarding its sampling schedule, the
system must sample at the reported schedule.
(b) Systems must collect samples within two
days before or two days after the dates indicated in their sampling schedule
(i.e., within a five-day period around the schedule date) unless one of the
conditions of paragraph (b)(i) or (ii) of this section applies.
(i) If an extreme condition or situation
exists that may pose danger to the sample collector, or that cannot be avoided
and causes the system to be unable to sample in the scheduled five-day period,
the system must sample as close to the scheduled date as is feasible unless the
Director approves an alternative sampling date. The system must submit an
explanation for the delayed sampling date to the Director concurrent with the
shipment of the sample to the laboratory.
(ii)
(A) If
a system is unable to report a valid analytical result for a scheduled sampling
date due to equipment failure, loss of or damage to the sample, failure to
comply with the analytical method requirements, including the quality control
requirements in R309-215-15(5), or the failure of an approved laboratory to
analyze the sample, then the system must collect a replacement
sample.
(B) The system must collect
the replacement sample not later than 21 days after receiving information that
an analytical result cannot be reported for the scheduled date unless the
system demonstrates that collecting a replacement sample within this time frame
is not feasible or the Director approves an alternative resampling date. The
system must submit an explanation for the delayed sampling date to the Director
concurrent with the shipment of the sample to the laboratory.
(c) Systems that fail
to meet the criteria of paragraph (b) of this section for any source water
sample required under R309-215-15(2) must revise their sampling schedules to
add dates for collecting all missed samples. Systems must submit the revised
schedule to the Director for approval prior to when the system begins
collecting the missed samples.
(4) Sampling locations.
(a) Systems required to conduct source water
monitoring under R309-215-15(2) must collect samples for each plant that treats
a surface water or GWUDI source. Where multiple plants draw water from the same
influent, such as the same pipe or intake, the Director may approve one set of
monitoring results to be used to satisfy the requirements of R309-215-15(2) for
all plants.
(b)
(i) Systems must collect source water samples
prior to chemical treatment, such as coagulants, oxidants and disinfectants,
unless the system meets the condition of paragraph (b)(ii) of this
section.
(ii) The Director may
approve a system to collect a source water sample after chemical treatment. To
grant this approval, the Director must determine that collecting a sample prior
to chemical treatment is not feasible for the system and that the chemical
treatment is unlikely to have a significant adverse effect on the analysis of
the sample.
(c) Systems
that recycle filter backwash water must collect source water samples prior to
the point of filter backwash water addition.
(d) Bank filtration.
(i) Systems that receive Cryptosporidium
treatment credit for bank filtration under
R309-200-5(5)(a)(ii)
must collect source water samples in the surface water prior to bank
filtration.
(ii) Systems that use
bank filtration as pretreatment to a filtration plant must collect source water
samples from the well (i.e., after bank filtration). Use of bank filtration
during monitoring must be consistent with routine operational practice. Systems
collecting samples after a bank filtration process may not receive treatment
credit for the bank filtration under R309-215-15(16)(c).
(e) Multiple sources. Systems with plants
that use multiple water sources, including multiple surface water sources and
blended surface water and ground water sources, must collect samples as
specified in paragraph (e)(i) or (ii) of this section. The use of multiple
sources during monitoring must be consistent with routine operational practice.
(i) If a sampling tap is available where the
sources are combined prior to treatment, systems must collect samples from the
tap.
(ii) If a sampling tap where
the sources are combined prior to treatment is not available, systems must
collect samples at each source near the intake on the same day and must follow
either paragraph (e)(ii)(A) or (B) of this section for sample analysis.
(A) Systems may composite samples from each
source into one sample prior to analysis. The volume of sample from each source
must be weighted according to the proportion of the source in the total plant
flow at the time the sample is collected.
(B) Systems may analyze samples from each
source separately and calculate a weighted average of the analysis results for
each sampling date. The weighted average must be calculated by multiplying the
analysis result for each source by the fraction the source contributed to total
plant flow at the time the sample was collected and then summing these
values.
(f)
Additional Requirements. Systems must submit a description of their sampling
location(s) to the Director at the same time as the sampling schedule required
under R309-215-15(3). This description must address the position of the
sampling location in relation to the system's water source(s) and treatment
processes, including pretreatment, points of chemical treatment, and filter
backwash recycle. If the Director does not respond to a system regarding
sampling location(s), the system must sample at the reported
location(s).
(5)
Analytical methods.
(a) Cryptosporidium.
Systems must analyze for Cryptosporidium using Method 1623: Cryptosporidium and
Giardia in Water by Filtration/IMS/FA, 2005, United States Environmental
Protection Agency, EPA-815-R-05-002 or Method 1622: Cryptosporidium in Water by
Filtration/IMS/FA, 2005, United States Environmental Protection Agency,
EPA-815-R-05-001, which are incorporated by reference. You may obtain a copy of
these methods online from
http://www.epa.gov/safewater/disinfection/lt2
or from the United States Environmental Protection Agency, Office of Ground
Water and Drinking Water, 1201 Constitution Ave., NW, Washington, DC 20460
(Telephone: 800-426-4791). You may inspect a copy at the Water Docket in the
EPA Docket Center, 1301 Constitution Ave., NW, Washington, DC, (Telephone:
202-566-2426) or at the National Archives and Records Administration (NARA).
For information on the availability of this material at NARA, call
202-741-6030, or go to:
http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.
You may also obtain a copy of these methods by contacting the Division of
Drinking Water at 801-536-4200.
(i) Systems
must analyze at least a 10 L sample or a packed pellet volume of at least 2 mL
as generated by the methods listed in paragraph (a) of this section. Systems
unable to process a 10 L sample must analyze as much sample volume as can be
filtered by two filters approved by EPA for the methods listed in paragraph (a)
of this section, up to a packed pellet volume of at least 2 mL.
(ii)
(A)
Matrix spike (MS) samples, as required by the methods in paragraph (a) of this
section, must be spiked and filtered by a laboratory approved for
Cryptosporidium analysis under R309-215-15(6).
(B) If the volume of the MS sample is greater
than 10 L, the system may filter all but 10 L of the MS sample in the field,
and ship the filtered sample and the remaining 10 L of source water to the
laboratory. In this case, the laboratory must spike the remaining 10 L of water
and filter it through the filter used to collect the balance of the sample in
the field.
(iii) Flow
cytometer-counted spiking suspensions must be used for MS samples and ongoing
precision and recovery (OPR) samples.
(b)
E. coli. Systems must use methods for enumeration of E. coli
in source water approved in
R309-200-4(3) and
(4).
(i) The time from sample collection to
initiation of analysis may not exceed 30 hours unless the system meets the
condition of paragraph (b)(ii) of this section.
(ii) The Director may approve on a
case-by-case basis the holding of an E. coli sample for up to 48 hours between
sample collection and initiation of analysis if the Director determines that
analyzing an E. coli sample within 30 hours is not feasible. E. coli samples
held between 30 to 48 hours must be analyzed by the Colilert reagent version of
Standard Method 9223B as listed in
R309-200-4(3) and
(4).
(iii) Systems must maintain samples between 0
deg.C and 10 deg. C during storage and transit to the laboratory.
(c) Turbidity. Systems must use
methods for turbidity measurement approved in
R309-200-4(3) and
(4).
(6) Approved laboratories.
(a) Cryptosporidium. Systems must have
Cryptosporidium samples analyzed by a laboratory that is approved under EPA's
Laboratory Quality Assurance Evaluation Program for Analysis of Cryptosporidium
in Water or a laboratory that has been certified for Cryptosporidium analysis
by an equivalent State laboratory certification program.
(b)
E. coli. Any laboratory certified by the EPA, the National
Environmental Laboratory Accreditation Conference or the State for total
coliform or fecal coliform analysis under
R309-200-4(3) and
(4) is approved for E. coli analysis under
this subpart when the laboratory uses the same technique for E. coli that the
laboratory uses for
R309-200-4(3),
(4) and in
R444-14-4(1).
(c) Turbidity. Measurements of
turbidity must be made by a party approved by the State.
(7) Reporting source water monitoring
results.
(a) Systems must report results from
the source water monitoring required under R309-215-15(2) no later than 10 days
after the end of the first month following the month when the sample is
collected.
(b)
(i) All systems serving at least 10,000
people must report the results from the initial source water monitoring
required under R309-215-15(2)(a) to EPA electronically at https://
intranet.epa.gov/lt2/.
(ii) If a
system is unable to report monitoring results electronically, the system may
use an alternative approach for reporting monitoring results that EPA
approves.
(c) Systems
serving fewer than 10,000 people must report results from the initial source
water monitoring required under R309-215-15(2)(a) to the Director.
(d) All systems must report results from the
second round of source water monitoring required under R309-215-15(2)(b) to the
Director.
(e) Systems must report
the applicable information in paragraphs (e)(i) and (ii) of this section for
the source water monitoring required under R309-215-15(2).
(i) Systems must report the following data
elements for each Cryptosporidium analysis:
(A) PWS ID.
(B) Facility ID.
(C) Sample collection date.
(D) Sample type (field or matrix
spike).
(E) Sample volume filtered
(L), to nearest 1/4 L.
(F) Was 100%
of filtered volume examined.
(G)
Number of oocysts counted.
(H) For
matrix spike samples, systems must also report the sample volume spiked and
estimated number of oocysts spiked. These data are not required for field
samples.
(I) For samples in which
less than 10 L is filtered or less than 100% of the sample volume is examined,
systems must also report the number of filters used and the packed pellet
volume.
(J) For samples in which
less than 100% of sample volume is examined, systems must also report the
volume of resuspended concentrate and volume of this resuspension processed
through immunomagnetic separation.
(ii) Systems must report the following data
elements for each E. coli analysis:
(A) PWS
ID.
(B) Facility ID.
(C) Sample collection date.
(D) Analytical method number.
(E) Method type.
(F) Source type (flowing stream,
lake/reservoir, GWUDI).
(H) Turbidity. (Systems serving fewer than
10,000 people that are not required to monitor for turbidity under
R309-215-15(2) are not required to report turbidity with their E. coli
results.)
(8) Grandfathering previously collected data.
(a)
(i)
Systems may comply with the initial source water monitoring requirements of
R309-215-15(2)(a) by grandfathering sample results collected before the system
is required to begin monitoring (i.e., previously collected data). To be
grandfathered, the sample results and analysis must meet the criteria in this
section and the Director must approve.
(ii) A filtered system may grandfather
Cryptosporidium samples to meet the requirements of R309-215-15(2)(a) when the
system does not have corresponding E. coli and turbidity samples. A system that
grandfathers Cryptosporidium samples without E. coli and turbidity samples is
not required to collect E. coli and turbidity samples when the system completes
the requirements for Cryptosporidium monitoring under
R309-215-15(2)(a).
(b)
E. coli sample analysis. The analysis of E. coli samples must
meet the analytical method and approved laboratory requirements of
R309-215-15(5) through R309-215-15(6).
(c) Cryptosporidium sample analysis. The
analysis of Cryptosporidium samples must meet the criteria in this paragraph.
(i) Laboratories analyzed Cryptosporidium
samples using one of the analytical methods in paragraphs (c)(i)(A) through (D)
of this section, which are incorporated by reference. You may obtain a copy of
these methods on-line from the United States Environmental Protection Agency,
Office of Ground Water and Drinking Water, 1201 Constitution Ave, NW,
Washington, DC 20460 (Telephone: 800-426-4791). You may inspect a copy at the
Water Docket in the EPA Docket Center, 1301 Constitution Ave., NW, Washington,
DC, (Telephone: 202-566-2426) or at the National Archives and Records
Administration (NARA). For information on the availability of this material at
NARA, call 202-741-6030, or go to:
http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.
You may also obtain a copy of these methods by contacting the Division of
Drinking Water at 801-536-4200.
(A) Method
1623: Cryptosporidium and Giardia in Water by Filtration/IMS/ FA, 2005, United
States Environmental Protection Agency, EPA-815-R-05-002.
(B) Method 1622: Cryptosporidium in Water by
Filtration/IMS/FA, 2005, United States Environmental Protection Agency,
EPA-815-R-05-001.
(C) Method 1623:
Cryptosporidium and Giardia in Water by Filtration/IMS/ FA, 2001, United States
Environmental Protection Agency, EPA-821-R-01-025.
(D) Method 1622: Cryptosporidium in Water by
Filtration/IMS/FA, 2001, United States Environmental Protection Agency,
EPA-821-R-01-026.
(E) Method 1623:
Cryptosporidium and Giardia in Water by Filtration/IMS/ FA, 1999, United States
Environmental Protection Agency, EPA-821-R-99-006.
(F) Method 1622: Cryptosporidium in Water by
Filtration/IMS/FA, 1999, United States Environmental Protection Agency,
EPA-821-R-99-001.
(ii)
For each Cryptosporidium sample, the laboratory analyzed at least 10 L of
sample or at least 2 mL of packed pellet or as much volume as could be filtered
by 2 filters that EPA approved for the methods listed in paragraph (c)(1) of
this section.
(d)
Sampling location. The sampling location must meet the conditions in
R309-215-15(4).
(e) Sampling
frequency. Cryptosporidium samples were collected no less frequently than each
calendar month on a regular schedule, beginning no earlier than January 1999.
Sample collection intervals may vary for the conditions specified in
R309-215-15(3)(b)(i) and (ii) if the system provides documentation of the
condition when reporting monitoring results.
(i) The Director may approve grandfathering
of previously collected data where there are time gaps in the sampling
frequency if the system conducts additional monitoring the Director specifies
to ensure that the data used to comply with the initial source water monitoring
requirements of R309-215-15(2)(a) are seasonally representative and
unbiased.
(ii) Systems may
grandfather previously collected data where the sampling frequency within each
month varied. If the Cryptosporidium sampling frequency varied, systems must
follow the monthly averaging procedure in R309-215-15(11)(b)(v) when
calculating the bin classification for filtered systems.
(f) Reporting monitoring results for
grandfathering. Systems that request to grandfather previously collected
monitoring results must report the following information by the applicable
dates listed in this paragraph. Systems serving at least 10,000 people must
report this information to EPA unless the Director approves reporting to the
Director rather than EPA. Systems serving fewer than 10,000 people must report
this information to the Director.
(i) Systems
must report that they intend to submit previously collected monitoring results
for grandfathering. This report must specify the number of previously collected
results the system will submit, the dates of the first and last sample, and
whether a system will conduct additional source water monitoring to meet the
requirements of R309-215-15(2)(a). Systems must report this information no
later than the date the sampling schedule under R309-215-15(3) is
required.
(ii) Systems must report
previously collected monitoring results for grandfathering, along with the
associated documentation listed in paragraphs (f)(ii)(A) through (D) of this
section, no later than two months after the applicable date listed in
R309-215-15(2)(c).
(A) For each sample
result, systems must report the applicable data elements in
R309-215-15(7).
(B) Systems must
certify that the reported monitoring results include all results the system
generated during the time period beginning with the first reported result and
ending with the final reported result. This applies to samples that were
collected from the sampling location specified for source water monitoring
under this subpart, not spiked, and analyzed using the laboratory's routine
process for the analytical methods listed in this section.
(C) Systems must certify that the samples
were representative of a plant's source water(s) and the source water(s) have
not changed. Systems must report a description of the sampling location(s),
which must address the position of the sampling location in relation to the
system's water source(s) and treatment processes, including points of chemical
addition and filter backwash recycle.
(D) For Cryptosporidium samples, the
laboratory or laboratories that analyzed the samples must provide a letter
certifying that the quality control criteria specified in the methods listed in
paragraph (c)(i) of this section were met for each sample batch associated with
the reported results. Alternatively, the laboratory may provide bench sheets
and sample examination report forms for each field, matrix spike, IPR, OPR, and
method blank sample associated with the reported results.
(g) If the Director determines
that a previously collected data set submitted for grandfathering was generated
during source water conditions that were not normal for the system, such as a
drought, the Director may disapprove the data. Alternatively, the Director may
approve the previously collected data if the system reports additional source
water monitoring data, as determined by the Director, to ensure that the data
set used under R309-215-15(11) represents average source water conditions for
the system.
(h) If a system submits
previously collected data that fully meet the number of samples required for
initial source water monitoring under R309-215-15(2)(a) and some of the data
are rejected due to not meeting the requirements of this section, systems must
conduct additional monitoring to replace rejected data on a schedule the
Director approves. Systems are not required to begin this additional monitoring
until two months after notification that data have been rejected and additional
monitoring is necessary.
(9) Disinfection Profiling and Benchmarking
Requirements - Requirements when making a significant change in disinfection
practice.
(a) Following the completion of
initial source water monitoring under R309-215-15(2)(a), a system that plans to
make a significant change to its disinfection practice, as defined in paragraph
(b) of this section, must develop disinfection profiles and calculate
disinfection benchmarks for Giardia lamblia and viruses as described in
R309-215-15(10). Prior to changing the disinfection practice, the system must
notify the Director and must include in this notice the information in
paragraphs (a)(i) through (iii) of this section.
(i) A completed disinfection profile and
disinfection benchmark for Giardia lamblia and viruses as described in
R309-215-15(10).
(ii) A description
of the proposed change in disinfection practice.
(iii) An analysis of how the proposed change
will affect the current level of disinfection.
(b) Significant changes to disinfection
practice are defined as follows:
(i) Changes
to the point of disinfection;
(ii)
Changes to the disinfectant(s) used in the treatment plant;
(iii) Changes to the disinfection process;
or
(iv) Any other modification
identified by the Director as a significant change to disinfection
practice.
(10) Developing the disinfection profile and
benchmark.
(a) Systems required to develop
disinfection profiles under R309-215-15(9) must follow the requirements of this
section. Systems must monitor at least weekly for a period of 12 consecutive
months to determine the total log inactivation for Giardia lamblia and viruses.
If systems monitor more frequently, the monitoring frequency must be evenly
spaced. Systems that operate for fewer than 12 months per year must monitor
weekly during the period of operation. Systems must determine log inactivation
for Giardia lamblia through the entire plant, based on CT
99.9 values in Tables 1.1 through 1.6, 2.1 and 3.1 of
Section 141.74(b) in the code of Federal Regulations as applicable (available
from the Division). Systems must determine log inactivation for viruses through
the entire treatment plant based on a protocol approved by the
Director.
(b) Systems with a single
point of disinfectant application prior to the entrance to the distribution
system must conduct the monitoring in paragraphs (b)(i) through (iv) of this
section. Systems with more than one point of disinfectant application must
conduct the monitoring in paragraphs (b)(i) through (iv) of this section for
each disinfection segment. Systems must monitor the parameters necessary to
determine the total inactivation ratio, using analytical methods in
R309-200-4(3) and
(4).
(i)
For systems using a disinfectant other than UV, the temperature of the
disinfected water must be measured at each residual disinfectant concentration
sampling point during peak hourly flow or at an alternative location approved
by the Director.
(ii) For systems
using chlorine, the pH of the disinfected water must be measured at each
chlorine residual disinfectant concentration sampling point during peak hourly
flow or at an alternative location approved by the Director.
(iii) The disinfectant contact time(s) (t)
must be determined during peak hourly flow.
(iv) The residual disinfectant
concentration(s) (C) of the water before or at the first customer and prior to
each additional point of disinfectant application must be measured during peak
hourly flow.
(c) In lieu
of conducting new monitoring under paragraph (b) of this section, systems may
elect to meet the requirements of paragraphs (c)(i) or (ii) of this section.
(i) Systems that have at least one year of
existing data that are substantially equivalent to data collected under the
provisions of paragraph (b) of this section may use these data to develop
disinfection profiles as specified in this section if the system has neither
made a significant change to its treatment practice nor changed sources since
the data were collected. Systems may develop disinfection profiles using up to
three years of existing data.
(ii)
Systems may use disinfection profile(s) developed under
R309-215-14 in lieu of developing a new profile if the system has neither made a
significant change to its treatment practice nor changed sources since the
profile was developed. Systems that have not developed a virus profile under
R309-251-14 must develop a virus profile using the same monitoring data on
which the Giardia lamblia profile is based.
(d) Systems must calculate the total
inactivation ratio for Giardia lamblia as specified in paragraphs (d)(i)
through (iii) of this section.
(i) Systems
using only one point of disinfectant application may determine the total
inactivation ratio for the disinfection segment based on either of the methods
in paragraph (d)(1)(i) or (ii) of this section.
(A) Determine one inactivation ratio
(CTcalc/CT99.9) before or at the first customer during
peak hourly flow.
(B) Determine
successive CTcalc/ CT99.9 values, representing
sequential inactivation ratios, between the point of disinfectant application
and a point before or at the first customer during peak hourly flow. The system
must calculate the total inactivation ratio by determining
(CTcalc/CT99.9) for each sequence and then adding the
(CTcalc/ CT99.9) values together to determine the sum of
(CTcalc/CT99.9).
(ii) Systems using more than one point of
disinfectant application before the first customer must determine the CT value
of each disinfection segment immediately prior to the next point of
disinfectant application, or for the final segment, before or at the first
customer, during peak hourly flow. The (CTcalc/ CT99.9)
value of each segment and the sum of (CTcalc/CT99.9)
must be calculated using the method in paragraph (d)(i)(B) of this
section.
(iii) The system must
determine the total logs of inactivation by multiplying the value calculated in
paragraph (d)(i) or (d)(ii) of this section by 3.0.
(iv) Systems must calculate the log of
inactivation for viruses using a protocol approved by the Director.
(e) Systems must use the
procedures specified in paragraphs (e)(i) and (ii) of this section to calculate
a disinfection benchmark.
(i) For each year
of profiling data collected and calculated under paragraphs (a) through (d) of
this section, systems must determine the lowest mean monthly level of both
Giardia lamblia and virus inactivation. Systems must determine the mean Giardia
lamblia and virus inactivation for each calendar month for each year of
profiling data by dividing the sum of daily or weekly Giardia lamblia and virus
log inactivation by the number of values calculated for that month.
(ii) The disinfection benchmark is the lowest
monthly mean value (for systems with one year of profiling data) or the mean of
the lowest monthly mean values (for systems with more than one year of
profiling data) of Giardia lamblia and virus log inactivation in each year of
profiling data.
(11) Treatment Technique Requirements - Bin
classification for filtered systems.
(a)
Following completion of the initial round of source water monitoring required
under R309-215-15(2)(a), filtered systems must calculate an initial
Cryptosporidium bin concentration for each plant for which monitoring was
required. Calculation of the bin concentration must use the Cryptosporidium
results reported under R309-215-15(2)(a) and must follow the procedures in
paragraphs (b)(i) through (v) of this section.
(b)
(i) For
systems that collect a total of at least 48 samples, the bin concentration is
equal to the arithmetic mean of all sample concentrations.
(ii) For systems that collect a total of at
least 24 samples, but not more than 47 samples, the bin concentration is equal
to the highest arithmetic mean of all sample concentrations in any 12
consecutive months during which Cryptosporidium samples were
collected.
(iii) For systems that
serve fewer than 10,000 people and monitor for Cryptosporidium for only one
year (i.e., collect 24 samples in 12 months), the bin concentration is equal to
the arithmetic mean of all sample concentrations.
(iv) For systems with plants operating only
part of the year that monitor fewer than 12 months per year under
R309-215-15(2)(e), the bin concentration is equal to the highest arithmetic
mean of all sample concentrations during any year of Cryptosporidium
monitoring.
(v) If the monthly
Cryptosporidium sampling frequency varies, systems must first calculate a
monthly average for each month of monitoring. Systems must then use these
monthly average concentrations, rather than individual sample concentrations,
in the applicable calculation for bin classification in paragraphs (b)(i)
through (iv) of this section.
(c) Filtered systems must determine their
initial bin classification from the following and using the Cryptosporidium bin
concentration calculated under paragraphs (a) and (b) of this section:
(i) Systems that are required to monitor for
Cryptosporidium under R309-215-15(2):
(A)
with a cryptosporidium concentration of less than 0.075 oocyst/L, the bin
classification is Bin 1.
(B) with a
cryptosporidium concentration of 0.075 oocysts/L to less than 1.0 oocysts/L,
the bin classification is Bin 2.
(C) with a cryptosporidium concentration of
1.0 oocysts/L to less than 3.0 oocysts/L, the bin classification is Bin
3.
(D) with a cryptosporidium
concentration of equal to or greater than 3.0 oocysts/L, the bin classification
is Bin 4.
(ii) Systems
serving fewer than 10,000 people and not required to monitor for
Cryptosporidium under R309-215-15(2)(a)(iii), the concentration of
cryptosporidium is not applicable and their bin classification is Bin
1.
(iii) Based on calculations in
paragraph (a) or (d) of this section, as applicable.
(d) Following completion of the second round
of source water monitoring required under R309-215-15(2)(b), filtered systems
must recalculate their Cryptosporidium bin concentration using the
Cryptosporidium results reported under R309-215-15(2)(b) and following the
procedures in paragraphs (b)(i) through (iv) of this section. Systems must then
redetermine their bin classification using this bin concentration and the table
in paragraph (c) of this section.
(e)
(i)
Filtered systems must report their initial bin classification under paragraph
(c) of this section to the Director for approval no later than 6 months after
the system is required to complete initial source water monitoring based on the
schedule in R309-215-15(2)(c).
(ii)
Systems must report their bin classification under paragraph (d) of this
section to the Director for approval no later than 6 months after the system is
required to complete the second round of source water monitoring based on the
schedule in R309-215-15(2)(c).
(iii) The bin classification report to the
Director must include a summary of source water monitoring data and the
calculation procedure used to determine bin classification.
(f) Failure to comply with the
conditions of paragraph (e) of this section is a violation of the treatment
technique requirement.
(12) Filtered system additional
Cryptosporidium treatment requirements.
(a)
Filtered systems must provide the level of additional treatment for
Cryptosporidium specified in this paragraph based on their bin classification
as determined under R309-215-15(11) and according to the schedule in
R309-215-15(13). The filtration treatment used by the system in this paragraph
must be utilized in full compliance with the requirements of
R309-200-5(5),
R309-200-7,
R309-215-8 and 9.
(i) If the system bin classification
is Bin 1 and the system uses:
(A)
Conventional filtration treatment including softening there is no additional
cryptosporidium treatment required.
(B) Direct filtration there is no additional
cryptosporidium treatment required.
(C) Slow sand or diatomaceous earth
filtration there is no additional cryptosporidium treatment required.
(D) Alternative filtration technologies there
is no additional cryptosporidium treatment required.
(ii) If the system bin classification is Bin
2 and the system uses:
(A) Conventional
filtration treatment including softening there is an additional 1-log
cryptosporidium treatment required.
(B) Direct filtration there is an additional
1.5-log cryptosporidium treatment required.
(C) Slow sand or diatomaceous earth
filtration there is an additional 1-log cryptosporidium treatment
required.
(D) Alternative
filtration technologies there is an additional cryptosporidium treatment
required as determined by the Director such that the total Cryptosporidium
removal an inactivation is at least 4.0-log.
(iii) If the system bin classification is Bin
3 and the system uses:
(A) Conventional
filtration treatment including softening there is an additional 2-log
cryptosporidium treatment required.
(B) Direct filtration there is an additional
2.5-log cryptosporidium treatment required.
(C) Slow sand or diatomaceous earth
filtration there is an additional 2-log cryptosporidium treatment
required.
(D) Alternative
filtration technologies there is an additional cryptosporidium treatment
required as determined by the Director such that the total Cryptosporidium
removal an inactivation is at least 5.0-log.
(iv) If the system bin classification is Bin
4 and the system uses:
(A) Conventional
filtration treatment including softening there is an additional 2.5-log
cryptosporidium treatment required.
(B) Direct filtration there is an additional
3-log cryptosporidium treatment required.
(C) Slow sand or diatomaceous earth
filtration there is an additional 2.5-log cryptosporidium treatment
required.
(D) Alternative
filtration technologies there is an additional cryptosporidium treatment
required as determined by the Director such that the total Cryptosporidium
removal an inactivation is at least 5.5-log.
(b)
(i)
Filtered systems must use one or more of the treatment and management options
listed in R309-215-15(14), termed the microbial toolbox, to comply with the
additional Cryptosporidium treatment required in paragraph (a) of this
section.
(ii) Systems classified in
Bin 3 and Bin 4 must achieve at least 1-log of the additional Cryptosporidium
treatment required under paragraph (a) of this section using either one or a
combination of the following: bag filters, bank filtration, cartridge filters,
chlorine dioxide, membranes, ozone, or UV, as described in R309-215-15(15)
through R309-215-15(19).
(c) Failure by a system in any month to
achieve treatment credit by meeting criteria in R309-215-15(15) through
R309-215-15(19) for microbial toolbox options that is at least equal to the
level of treatment required in paragraph (a) of this section is a violation of
the treatment technique requirement.
(d) If the Director determines during a
sanitary survey or an equivalent source water assessment that after a system
completed the monitoring conducted under R309-215-15(2)(a) or
R309-215-15(2)(b), significant changes occurred in the system's watershed that
could lead to increased contamination of the source water by Cryptosporidium,
the system must take actions specified by the Director to address the
contamination. These actions may include additional source water monitoring
and/or implementing microbial toolbox options listed in
R309-215-15(14).
(13)
Schedule for compliance with Cryptosporidium treatment requirements.
(a) Following initial bin classification
under R309-215-15(11)(c), filtered systems must provide the level of treatment
for Cryptosporidium required under R309-215-15(12) according to the schedule in
paragraph (c) of this section.
(b)
Cryptosporidium treatment compliance dates.
(i) Systems that serve at least 100,000
people must comply with Cryptosporidium treatment requirements no later than
April 1, 2012.
(ii) Systems that
serve from 50,000 to 99,999 people must comply with Cryptosporidium treatment
requirements no later than October 1, 2012.
(iii) Systems that serve from 10,000 to
49,999 people must comply with Cryptosporidium treatment requirements no later
than October 1, 2013.
(iv) Systems
that serve less than 10,000 people must comply with Cryptosporidium treatment
requirements no later than October 1, 2014.
(v) The Director may allow up to an
additional two years for complying with the treatment requirement for systems
making capital improvements.
(c) If the bin classification for a filtered
system changes following the second round of source water monitoring, as
determined under R309-215-15(11)(d), the system must provide the level of
treatment for Cryptosporidium required under R309-215-15(12) on a schedule the
Director approves.
(14)
Microbial toolbox options for meeting Cryptosporidium treatment requirements.
(a) Systems receive the treatment credits
listed in the table in paragraph (b) of this section by meeting the conditions
for microbial toolbox options described in R309-215-15(15) through
R309-215-15(19). Systems apply these treatment credits to meet the treatment
requirements in R309-215-15(12).
(b) The following sub-section summarizes
options in the microbial toolbox and the Cryptosporidium treatment credit with
design and implementation criteria.
(i)
Source Protection and Management Toolbox Options:
(A) Watershed control program: 0.5-log credit
for Director-approved program comprising required elements, annual program
status report to Director, and regular watershed survey. Specific criteria are
in R309-215-15(15) (a).
(B)
Alternative source/intake management: No prescribed credit. Systems may conduct
simultaneous monitoring for treatment bin classification at alternative intake
locations or under alternative intake management strategies. Specific criteria
are in R309-215-15(15) (b).
(ii) Pre Filtration Toolbox Options:
(A) Presedimentation basin with coagulation:
0.5-log credit during any month that presedimentation basins achieve a monthly
mean reduction of 0.5-log or greater in turbidity or alternative
Director-approved performance criteria. To be eligible, basins must be operated
continuously with coagulant addition and all plant flow must pass through
basins. Specific criteria are in R309-215-15(16) (a).
(B) Two-stage lime softening: 0.5-log credit
for two-stage softening where chemical addition and hardness precipitation
occur in both stages. All plant flow must pass through both stages.
Single-stage softening is credited as equivalent to conventional treatment.
Specific criteria are in R309-215-15(16) (b).
(C) Bank filtration: 0.5-log credit for
25-foot setback; 1.0-log credit for 50-foot setback; aquifer must be
unconsolidated sand containing at least 10 percent fines; average turbidity in
wells must be less than 1 NTU. Systems using wells followed by filtration when
conducting source water monitoring must sample the well to determine bin
classification and are not eligible for additional credit. Specific criteria
are in R309-215-15(16) (c).
(iii) Treatment Performance Toolbox Options:
(A) Combined filter performance: 0.5-log
credit for combined filter effluent turbidity less than or equal to 0.15 NTU in
at least 95 percent of measurements each month. Specific criteria are in
R309-215-15(17) (a).
(B) Individual
filter performance: 0.5-log credit (in addition to 0.5-log combined filter
performance credit) if individual filter effluent turbidity is less than or
equal to 0.15 NTU in at least 95 percent of samples each month in each filter
and is never greater than 0.3 NTU in two consecutive measurements in any
filter. Specific criteria are in R309-215-15(17) (b).
(C) Demonstration of performance: Credit
awarded to unit process or treatment train based on a demonstration to the
Director with a Director-approved protocol. Specific criteria are in
R309-215-15(17) (c).
(iv) Additional Filtration Toolbox Options:
(A) Bag or cartridge filters (individual
filters): Up to 2-log credit based on the removal efficiency demonstrated
during challenge testing with a 1.0-log factor of safety. Specific criteria are
in R309-215-15(18) (a).
(B) Bag or
cartridge filters (in series): Up to 2.5-log credit based on the removal
efficiency demonstrated during challenge testing with a 0.5-log factor of
safety. Specific criteria are in R309-215-15(18) (a).
(C) Membrane filtration: Log credit
equivalent to removal efficiency demonstrated in challenge test for device if
supported by direct integrity testing. Specific criteria are in R309-215-15(18)
(b).
(D) Second stage filtration:
0.5-log credit for second separate granular media filtration stage if treatment
train includes coagulation prior to first filter. Specific criteria are in
R309-215-15(18) (c).
(E) Slow sand
filters: 2.5-log credit as a secondary filtration step; 3.0-log credit as a
primary filtration process. No prior chlorination for either option. Specific
criteria are in R309-215-15(18) (d).
(v) Inactivation Toolbox Options:
(A) Chlorine dioxide: Log credit based on
measured CT in relation to CT table. Specific criteria in R309-215-15(19)
(b).
(B) Ozone: Log credit based on
measured CT in relation to CT table. Specific criteria in R309-215-15(19)
(b).
(C) UV: Log credit based on
validated UV dose in relation to UV dose table; reactor validation testing
required to establish UV dose and associated operating conditions. Specific
criteria in R309-215-15(19) (d).
(15) Source toolbox components.
(a) Watershed control program. Systems
receive 0.5-log Cryptosporidium treatment credit for implementing a watershed
control program that meets the requirements of this section.
(i) Systems that intend to apply for the
watershed control program credit must notify the Director of this intent no
later than two years prior to the treatment compliance date applicable to the
system in R309-215-15(13).
(ii)
Systems must submit to the Director a proposed watershed control plan no later
than one year before the applicable treatment compliance date in
R309-215-15(13). The Director must approve the watershed control plan for the
system to receive watershed control program treatment credit. The watershed
control plan must include the elements in paragraphs (a)(ii)(A) through (D) of
this section.
(A) Identification of an ''area
of influence'' outside of which the likelihood of Cryptosporidium or fecal
contamination affecting the treatment plant intake is not significant. This is
the area to be evaluated in future watershed surveys under paragraph (a)(v)(B)
of this section.
(B) Identification
of both potential and actual sources of Cryptosporidium contamination and an
assessment of the relative impact of these sources on the system's source water
quality.
(C) An analysis of the
effectiveness and feasibility of control measures that could reduce
Cryptosporidium loading from sources of contamination to the system's source
water.
(D) A statement of goals and
specific actions the system will undertake to reduce source water
Cryptosporidium levels. The plan must explain how the actions are expected to
contribute to specific goals, identify watershed partners and their roles,
identify resource requirements and commitments, and include a schedule for plan
implementation with deadlines for completing specific actions identified in the
plan.
(iii) Systems with
existing watershed control programs (i.e., programs in place on January 5,
2006) are eligible to seek this credit. Their watershed control plans must meet
the criteria in paragraph (a)(ii) of this section and must specify ongoing and
future actions that will reduce source water Cryptosporidium levels.
(iv) If the Director does not respond to a
system regarding approval of a watershed control plan submitted under this
section and the system meets the other requirements of this section, the
watershed control program will be considered approved and 0.5 log
Cryptosporidium treatment credit will be awarded unless and until the Director
subsequently withdraws such approval.
(v) Systems must complete the actions in
paragraphs (a)(v)(A) through (C) of this section to maintain the 0.5-log
credit.
(A) Submit an annual watershed
control program status report to the Director. The annual watershed control
program status report must describe the system's implementation of the approved
plan and assess the adequacy of the plan to meet its goals. It must explain how
the system is addressing any shortcomings in plan implementation, including
those previously identified by the Director or as the result of the watershed
survey conducted under paragraph (a)(v)(B) of this section. It must also
describe any significant changes that have occurred in the watershed since the
last watershed sanitary survey. If a system determines during implementation
that making a significant change to its approved watershed control program is
necessary, the system must notify the Director prior to making any such
changes. If any change is likely to reduce the level of source water
protection, the system must also list in its notification the actions the
system will take to mitigate this effect.
(B) Undergo a watershed sanitary survey every
three years for community water systems and every five years for non-community
water systems and submit the survey report to the Director. The survey must be
conducted according to State guidelines and by persons the Director approves.
(I) The watershed sanitary survey must meet
the following criteria: encompass the region identified in the
Director-approved watershed control plan as the area of influence; assess the
implementation of actions to reduce source water Cryptosporidium levels; and
identify any significant new sources of Cryptosporidium.
(II) If the Director determines that
significant changes may have occurred in the watershed since the previous
watershed sanitary survey, systems must undergo another watershed sanitary
survey by a date the Director requires, which may be earlier than the regular
date in paragraph (a)(v)(B) of this section.
(C) The system must make the watershed
control plan, annual status reports, and watershed sanitary survey reports
available to the public upon request. These documents must be in a plain
language style and include criteria by which to evaluate the success of the
program in achieving plan goals. The Director may approve systems to withhold
from the public portions of the annual status report, watershed control plan,
and watershed sanitary survey based on water supply security
considerations.
(vi) If
the Director determines that a system is not carrying out the approved
watershed control plan, the Director may withdraw the watershed control program
treatment credit.
(b)
Alternative source.
(i) A system may conduct
source water monitoring that reflects a different intake location (either in
the same source or for an alternate source) or a different procedure for the
timing or level of withdrawal from the source (alternative source monitoring).
If the Director approves, a system may determine its bin classification under
R309-215-15(11) based on the alternative source monitoring results.
(ii) If systems conduct alternative source
monitoring under paragraph (b)(i) of this section, systems must also monitor
their current plant intake concurrently as described in
R309-215-15(2).
(iii) Alternative
source monitoring under paragraph (b)(i) of this section must meet the
requirements for source monitoring to determine bin classification, as
described in R309-215-15(2) through R309-215-15(7). Systems must report the
alternative source monitoring results to the Director, along with supporting
information documenting the operating conditions under which the samples were
collected.
(iv) If a system
determines its bin classification under R309-215-15(11) using alternative
source monitoring results that reflect a different intake location or a
different procedure for managing the timing or level of withdrawal from the
source, the system must relocate the intake or permanently adopt the withdrawal
procedure, as applicable, no later than the applicable treatment compliance
date in R309-215-15(13).
(16) Pre-filtration treatment toolbox
components.
(a) Presedimentation. Systems
receive 0.5-log Cryptosporidium treatment credit for a presedimentation basin
during any month the process meets the criteria in this paragraph.
(i) The presedimentation basin must be in
continuous operation and must treat the entire plant flow taken from a surface
water or GWUDI source.
(ii) The
system must continuously add a coagulant to the presedimentation
basin.
(iii) The presedimentation
basin must achieve the performance criteria in paragraph (iii)(A) or (B) of
this section.
(A) Demonstrates at least
0.5-log mean reduction of influent turbidity. This reduction must be determined
using daily turbidity measurements in the presedimentation process influent and
effluent and must be calculated as follows: log10(monthly mean of daily
influent turbidity) minus log10(monthly mean of daily effluent
turbidity).
(B) Complies with
Director-approved performance criteria that demonstrate at least 0.5-log mean
removal of micron-sized particulate material through the presedimentation
process.
(b)
Two-stage lime softening. Systems receive an additional 0.5-log Cryptosporidium
treatment credit for a two-stage lime softening plant if chemical addition and
hardness precipitation occur in two separate and sequential softening stages
prior to filtration. Both softening stages must treat the entire plant flow
taken from a surface water or GWUDI source.
(c) Bank filtration. Systems receive
Cryptosporidium treatment credit for bank filtration that serves as
pretreatment to a filtration plant by meeting the criteria in this paragraph.
Systems using bank filtration when they begin source water monitoring under
R309-215-15(2)(a) must collect samples as described in R309-215-15(4)(d) and
are not eligible for this credit.
(i) Wells
with a ground water flow path of at least 25 feet receive 0.5-log treatment
credit; wells with a ground water flow path of at least 50 feet receive 1.0-log
treatment credit. The ground water flow path must be determined as specified in
paragraph (c)(iv) of this section.
(ii) Only wells in granular aquifers are
eligible for treatment credit. Granular aquifers are those comprised of sand,
clay, silt, rock fragments, pebbles or larger particles, and minor cement. A
system must characterize the aquifer at the well site to determine aquifer
properties. Systems must extract a core from the aquifer and demonstrate that
in at least 90 percent of the core length, grains less than 1.0 mm in diameter
constitute at least 10 percent of the core material.
(iii) Only horizontal and vertical wells are
eligible for treatment credit.
(iv)
For vertical wells, the ground water flow path is the measured distance from
the edge of the surface water body under high flow conditions (determined by
the 100 year floodplain elevation boundary or by the floodway, as defined in
Federal Emergency Management Agency flood hazard maps) to the well screen. For
horizontal wells, the ground water flow path is the measured distance from the
bed of the river under normal flow conditions to the closest horizontal well
lateral screen.
(v) Systems must
monitor each wellhead for turbidity at least once every four hours while the
bank filtration process is in operation. If monthly average turbidity levels,
based on daily maximum values in the well, exceed 1 NTU, the system must report
this result to the Director and conduct an assessment within 30 days to
determine the cause of the high turbidity levels in the well. If the Director
determines that microbial removal has been compromised, the Director may revoke
treatment credit until the system implements corrective actions approved by the
Director to remediate the problem.
(vi) Springs and infiltration galleries are
not eligible for treatment credit under this section, but are eligible for
credit under R309-215-15(17)(c).
(vii) Bank filtration demonstration of
performance. The Director may approve Cryptosporidium treatment credit for bank
filtration based on a demonstration of performance study that meets the
criteria in this paragraph. This treatment credit may be greater than 1.0-log
and may be awarded to bank filtration that does not meet the criteria in
paragraphs (c)(i)-(v) of this section.
(A)
The study must follow a Director-approved protocol and must involve the
collection of data on the removal of Cryptosporidium or a surrogate for
Cryptosporidium and related hydrogeologic and water quality parameters during
the full range of operating conditions.
(B) The study must include sampling both from
the production well(s) and from monitoring wells that are screened and located
along the shortest flow path between the surface water source and the
production well(s).
(17) Treatment performance toolbox
components.
(a) Combined filter performance.
Systems using conventional filtration treatment or direct filtration treatment
receive an additional 0.5-log Cryptosporidium treatment credit during any month
the system meets the criteria in this paragraph. Combined filter effluent (CFE)
turbidity must be less than or equal to 0.15 NTU in at least 95 percent of the
measurements. Turbidity must be measured as described in
R309-200-4(3) and
(4).
(b) Individual filter performance. Systems
using conventional filtration treatment or direct filtration treatment receive
0.5-log Cryptosporidium treatment credit, which can be in addition to the
0.5-log credit under paragraph (a) of this section, during any month the system
meets the criteria in this paragraph. Compliance with these criteria must be
based on individual filter turbidity monitoring as described in
R309-215-9(4)
or (5), as applicable.
(i) The filtered water turbidity for each
individual filter must be less than or equal to 0.15 NTU in at least 95 percent
of the measurements recorded each month.
(ii) No individual filter may have a measured
turbidity greater than 0.3 NTU in two consecutive measurements taken 15 minutes
apart.
(iii) Any system that has
received treatment credit for individual filter performance and fails to meet
the requirements of paragraph (b)(i) or (ii) of this section during any month
does not receive a treatment technique violation under R309-215-15(12)(c) if
the Director determines the following:
(A)
The failure was due to unusual and short-term circumstances that could not
reasonably be prevented through optimizing treatment plant design, operation,
and maintenance.
(B) The system has
experienced no more than two such failures in any calendar year.
(c) Demonstration of
performance. The Director may approve Cryptosporidium treatment credit for
drinking water treatment processes based on a demonstration of performance
study that meets the criteria in this paragraph. This treatment credit may be
greater than or less than the prescribed treatment credits in R309-215-15(12)
or R309-215-15(16) through R309-215-15(19) and may be awarded to treatment
processes that do not meet the criteria for the prescribed credits.
(i) Systems cannot receive the prescribed
treatment credit for any toolbox box option in R309-215-15(16) through
R309-215-15(19) if that toolbox option is included in a demonstration of
performance study for which treatment credit is awarded under this
paragraph.
(ii) The demonstration
of performance study must follow a Director-approved protocol and must
demonstrate the level of Cryptosporidium reduction the treatment process will
achieve under the full range of expected operating conditions for the
system.
(iii) Approval by the
Director must be in writing and may include monitoring and treatment
performance criteria that the system must demonstrate and report on an ongoing
basis to remain eligible for the treatment credit. The Director may designate
such criteria where necessary to verify that the conditions under which the
demonstration of performance credit was approved are maintained during routine
operation.
(18) Additional filtration toolbox
components.
(a) Bag and cartridge filters.
Systems receive Cryptosporidium treatment credit of up to 2.0-log for
individual bag or cartridge filters and up to 2.5-log for bag or cartridge
filters operated in series by meeting the criteria in paragraphs (a)(i) through
(x) of this section. To be eligible for this credit, systems must report the
results of challenge testing that meets the requirements of paragraphs (a)(ii)
through (ix) of this section to the Director. The filters must treat the entire
plant flow taken from a surface water source.
(i) The Cryptosporidium treatment credit
awarded to bag or cartridge filters must be based on the removal efficiency
demonstrated during challenge testing that is conducted according to the
criteria in paragraphs (a)(ii) through (a)(ix) of this section. A factor of
safety equal to 1-log for individual bag or cartridge filters and 0.5-log for
bag or cartridge filters in series must be applied to challenge testing results
to determine removal credit. Systems may use results from challenge testing
conducted prior to January 5, 2006 if the prior testing was consistent with the
criteria specified in paragraphs (a)(ii) through (ix) of this
section.
(ii) Challenge testing
must be performed on full-scale bag or cartridge filters, and the associated
filter housing or pressure vessel, that are identical in material and
construction to the filters and housings the system will use for removal of
Cryptosporidium. Bag or cartridge filters must be challenge tested in the same
configuration that the system will use, either as individual filters or as a
series configuration of filters.
(iii) Challenge testing must be conducted
using Cryptosporidium or a surrogate that is removed no more efficiently than
Cryptosporidium. The microorganism or surrogate used during challenge testing
is referred to as the challenge particulate. The concentration of the challenge
particulate must be determined using a method capable of discreetly quantifying
the specific microorganism or surrogate used in the test; gross measurements
such as turbidity may not be used.
(iv) The maximum feed water concentration
that can be used during a challenge test must be based on the detection limit
of the challenge particulate in the filtrate (i.e., filtrate detection limit)
and must be calculated using the following equation: Maximum Feed Concentration
= 1 x 104 x (Filtrate Detection Limit).
(v) Challenge testing must be conducted at
the maximum design flow rate for the filter as specified by the
manufacturer.
(vi) Each filter
evaluated must be tested for a duration sufficient to reach 100 percent of the
terminal pressure drop, which establishes the maximum pressure drop under which
the filter may be used to comply with the requirements of this
subpart.
(vii) Removal efficiency
of a filter must be determined from the results of the challenge test and
expressed in terms of log removal values using the following equation: LRV =
LOG10(Cf)-
LOG10(Cp) Where: LRV = log
removal value demonstrated during challenge testing; Cf
= the feed concentration measured during the challenge test; and
Cp = the filtrate concentration measured during the
challenge test. In applying this equation, the same units must be used for the
feed and filtrate concentrations. If the challenge particulate is not detected
in the filtrate, then the term Cp must be set equal to
the detection limit.
(viii) Each
filter tested must be challenged with the challenge particulate during three
periods over the filtration cycle: within two hours of start-up of a new
filter; when the pressure drop is between 45 and 55 percent of the terminal
pressure drop; and at the end of the cycle after the pressure drop has reached
100 percent of the terminal pressure drop. An LRV must be calculated for each
of these challenge periods for each filter tested. The LRV for the filter
(LRVfilter) must be assigned the value of the minimum
LRV observed during the three challenge periods for that filter.
(ix) If fewer than 20 filters are tested, the
overall removal efficiency for the filter product line must be set equal to the
lowest LRVfilter among the filters tested. If 20 or more
filters are tested, the overall removal efficiency for the filter product line
must be set equal to the 10th percentile of the set of
LRVfilter values for the various filters tested. The
percentile is defined by (i/(n+1)) where i is the rank of n individual data
points ordered lowest to highest. If necessary, the 10th percentile may be
calculated using linear interpolation.
(x) If a previously tested filter is modified
in a manner that could change the removal efficiency of the filter product
line, challenge testing to demonstrate the removal efficiency of the modified
filter must be conducted and submitted to the Director.
(b) Membrane filtration.
(i) Systems receive Cryptosporidium treatment
credit for membrane filtration that meets the criteria of this paragraph.
Membrane cartridge filters that meet the definition of membrane filtration in
R309-110 are eligible for this credit. The level of treatment credit a system
receives is equal to the lower of the values determined under paragraph
(b)(i)(A) and (B) of this section.
(A) The
removal efficiency demonstrated during challenge testing conducted under the
conditions in paragraph (b)(ii) of this section.
(B) The maximum removal efficiency that can
be verified through direct integrity testing used with the membrane filtration
process under the conditions in paragraph (b)(iii) of this section.
(ii) Challenge Testing. The
membrane used by the system must undergo challenge testing to evaluate removal
efficiency, and the system must report the results of challenge testing to the
Director. Challenge testing must be conducted according to the criteria in
paragraphs (b)(ii)(A) through (G) of this section. Systems may use data from
challenge testing conducted prior to January 5, 2006 if the prior testing was
consistent with the criteria in paragraphs (b)(ii)(A) through (G) of this
section.
(A) Challenge testing must be
conducted on either a full-scale membrane module, identical in material and
construction to the membrane modules used in the system's treatment facility,
or a smaller-scale membrane module, identical in material and similar in
construction to the full-scale module. A module is defined as the smallest
component of a membrane unit in which a specific membrane surface area is
housed in a device with a filtrate outlet structure.
(B) Challenge testing must be conducted using
Cryptosporidium oocysts or a surrogate that is removed no more efficiently than
Cryptosporidium oocysts. The organism or surrogate used during challenge
testing is referred to as the challenge particulate. The concentration of the
challenge particulate, in both the feed and filtrate water, must be determined
using a method capable of discretely quantifying the specific challenge
particulate used in the test; gross measurements such as turbidity may not be
used.
(C) The maximum feed water
concentration that can be used during a challenge test is based on the
detection limit of the challenge particulate in the filtrate and must be
determined according to the following equation: Maximum Feed Concentration =
3.16 x 106 x (Filtrate Detection Limit).
(D) Challenge testing must be conducted under
representative hydraulic conditions at the maximum design flux and maximum
design process recovery specified by the manufacturer for the membrane module.
Flux is defined as the throughput of a pressure driven membrane process
expressed as flow per unit of membrane area. Recovery is defined as the
volumetric percent of feed water that is converted to filtrate over the course
of an operating cycle uninterrupted by events such as chemical cleaning or a
solids removal process (i.e., backwashing).
(E) Removal efficiency of a membrane module
must be calculated from the challenge test results and expressed as a log
removal value according to the following equation: LRV =
LOG10(Cf) -
LOG10(Cp) Where: LRV = log
removal value demonstrated during the challenge test; Cf
= the feed concentration measured during the challenge test; and
Cp = the filtrate concentration measured during the
challenge test. Equivalent units must be used for the feed and filtrate
concentrations. If the challenge particulate is not detected in the filtrate,
the term Cp is set equal to the detection limit for the
purpose of calculating the LRV. An LRV must be calculated for each membrane
module evaluated during the challenge test.
(F) The removal efficiency of a membrane
filtration process demonstrated during challenge testing must be expressed as a
log removal value (LRVC-Test). If fewer than 20 modules
are tested, then LRVC-Test is equal to the lowest of the
representative LRVs among the modules tested. If 20 or more modules are tested,
then LRVC-Test is equal to the 10th percentile of the
representative LRVs among the modules tested. The percentile is defined by
(i/(n+1)) where i is the rank of n individual data points ordered lowest to
highest. If necessary, the 10th percentile may be calculated using linear
interpolation.
(G) The challenge
test must establish a quality control release value (QCRV) for a
non-destructive performance test that demonstrates the Cryptosporidium removal
capability of the membrane filtration module. This performance test must be
applied to each production membrane module used by the system that was not
directly challenge tested in order to verify Cryptosporidium removal
capability. Production modules that do not meet the established QCRV are not
eligible for the treatment credit demonstrated during the challenge
test.
(H) If a previously tested
membrane is modified in a manner that could change the removal efficiency of
the membrane or the applicability of the non-destructive performance test and
associated QCRV, additional challenge testing to demonstrate the removal
efficiency of, and determine a new QCRV for, the modified membrane must be
conducted and submitted to the Director.
(iii) Direct integrity testing. Systems must
conduct direct integrity testing in a manner that demonstrates a removal
efficiency equal to or greater than the removal credit awarded to the membrane
filtration process and meets the requirements described in paragraphs
(b)(iii)(A) through (F) of this section. A direct integrity test is defined as
a physical test applied to a membrane unit in order to identify and isolate
integrity breaches (i.e., one or more leaks that could result in contamination
of the filtrate).
(A) The direct integrity
test must be independently applied to each membrane unit in service. A membrane
unit is defined as a group of membrane modules that share common valving that
allows the unit to be isolated from the rest of the system for the purpose of
integrity testing or other maintenance.
(B) The direct integrity method must have a
resolution of 3 micrometers or less, where resolution is defined as the size of
the smallest integrity breach that contributes to a response from the direct
integrity test.
(C) The direct
integrity test must have a sensitivity sufficient to verify the log treatment
credit awarded to the membrane filtration process by the Director, where
sensitivity is defined as the maximum log removal value that can be reliably
verified by a direct integrity test. Sensitivity must be determined using the
approach in either paragraph (b)(iii)(C)(I) or (II) of this section as
applicable to the type of direct integrity test the system uses.
(I) For direct integrity tests that use an
applied pressure or vacuum, the direct integrity test sensitivity must be
calculated according to the following equation: LRVDIT =
LOG10 (Qp /(VCF x
Qbreach)) Where: LRVDIT = the
sensitivity of the direct integrity test; Qp = total
design filtrate flow from the membrane unit; Qbreach =
flow of water from an integrity breach associated with the smallest integrity
test response that can be reliably measured, and VCF = volumetric concentration
factor. The volumetric concentration factor is the ratio of the suspended
solids concentration on the high pressure side of the membrane relative to that
in the feed water.
(II) For direct
integrity tests that use a particulate or molecular marker, the direct
integrity test sensitivity must be calculated according to the following
equation: LRVDIT =
LOG10(Cf)-
LOG10(Cp) Where: LRVDIT = the
sensitivity of the direct integrity test; Cf = the typical feed concentration
of the marker used in the test; and Cp = the filtrate concentration of the
marker from an integral membrane unit.
(D) Systems must establish a control limit
within the sensitivity limits of the direct integrity test that is indicative
of an integral membrane unit capable of meeting the removal credit awarded by
the Director.
(E) If the result of
a direct integrity test exceeds the control limit established under paragraph
(b)(iii)(D) of this section, the system must remove the membrane unit from
service. Systems must conduct a direct integrity test to verify any repairs,
and may return the membrane unit to service only if the direct integrity test
is within the established control limit.
(F) Systems must conduct direct integrity
testing on each membrane unit at a frequency of not less than once each day
that the membrane unit is in operation. The Director may approve less frequent
testing, based on demonstrated process reliability, the use of multiple
barriers effective for Cryptosporidium, or reliable process
safeguards.
(iv)
Indirect integrity monitoring. Systems must conduct continuous indirect
integrity monitoring on each membrane unit according to the criteria in
paragraphs (b)(iv)(A) through (E) of this section. Indirect integrity
monitoring is defined as monitoring some aspect of filtrate water quality that
is indicative of the removal of particulate matter. A system that implements
continuous direct integrity testing of membrane units in accordance with the
criteria in paragraphs (b)(iii)(A) through (E) of this section is not subject
to the requirements for continuous indirect integrity monitoring. Systems must
submit a monthly report to the Director summarizing all continuous indirect
integrity monitoring results triggering direct integrity testing and the
corrective action that was taken in each case.
(A) Unless the Director approves an
alternative parameter, continuous indirect integrity monitoring must include
continuous filtrate turbidity monitoring.
(B) Continuous monitoring must be conducted
at a frequency of no less than once every 15 minutes.
(C) Continuous monitoring must be separately
conducted on each membrane unit.
(D) If indirect integrity monitoring includes
turbidity and if the filtrate turbidity readings are above 0.15 NTU for a
period greater than 15 minutes (i.e., two consecutive 15-minute readings above
0.15 NTU), direct integrity testing must immediately be performed on the
associated membrane unit as specified in paragraphs (b)(iii)(A) through (E) of
this section.
(E) If indirect
integrity monitoring includes a Director-approved alternative parameter and if
the alternative parameter exceeds a Director-approved control limit for a
period greater than 15 minutes, direct integrity testing must immediately be
performed on the associated membrane units as specified in paragraphs
(b)(iii)(A) through (E) of this section.
(c) Second stage filtration. Systems receive
0.5-log Cryptosporidium treatment credit for a separate second stage of
filtration that consists of sand, dual media, GAC, or other fine grain media
following granular media filtration if the Director approves. To be eligible
for this credit, the first stage of filtration must be preceded by a
coagulation step and both filtration stages must treat the entire plant flow
taken from a surface water or GWUDI source. A cap, such as GAC, on a single
stage of filtration is not eligible for this credit. The Director must approve
the treatment credit based on an assessment of the design characteristics of
the filtration process.
(d) Slow
sand filtration (as secondary filter). Systems are eligible to receive 2.5-log
Cryptosporidium treatment credit for a slow sand filtration process that
follows a separate stage of filtration if both filtration stages treat entire
plant flow taken from a surface water or GWUDI source and no disinfectant
residual is present in the influent water to the slow sand filtration process.
The Director must approve the treatment credit based on an assessment of the
design characteristics of the filtration process. This paragraph does not apply
to treatment credit awarded to slow sand filtration used as a primary
filtration process.
(19)
Inactivation toolbox components.
(a)
Calculation of CT values.
(i) CT is the
product of the disinfectant contact time (T, in minutes) and disinfectant
concentration (C, in milligrams per liter). Systems with treatment credit for
chlorine dioxide or ozone under paragraph (b) or (c) of this section must
calculate CT at least once each day, with both C and T measured during peak
hourly flow as specified in
R309-200-4(3) and
(4).
(ii) Systems with several disinfection
segments in sequence may calculate CT for each segment, where a disinfection
segment is defined as a treatment unit process with a measurable disinfectant
residual level and a liquid volume. Under this approach, systems must add the
Cryptosporidium CT values in each segment to determine the total CT for the
treatment plant.
(b) CT
values for chlorine dioxide and ozone.
(i)
Systems receive the Cryptosporidium treatment credit listed in this paragraph
by meeting the corresponding chlorine dioxide CT value for the applicable water
temperature, as described in paragraph (a) of this section.
(i) CT values ((MG)(MIN)/L) for
Cryptosporidium inactivation by Chlorine Dioxide listed by the log credit with
inactivation listed by water temperature in degrees Celsius.
(A) 0.25 Log Credit:
(I) less than or equal to 0.5 degrees:
159;
(II) 1 degree: 153;
(III) 2 degrees: 140;
(IV) 3 degrees: 128;
(V) 5 degrees: 107;
(VI) 7 degrees: 90;
(VII) 10 degrees: 69;
(VIII) 15 degrees: 45;
(IX) 20 degrees: 29;
(X) 25 degrees: 19; and
(XI) 30 degrees: 12.
(B) 0.5 Log Credit:
(I) less than or equal to 0.5 degrees:
319;
(II) 1 degree: 305;
(III) 2 degrees: 279;
(IV) 3 degrees: 256;
(V) 5 degrees: 214;
(VI) 7 degrees: 180;
(VII) 10 degrees: 138;
(VIII) 15 degrees: 89;
(IX) 20 degrees: 58;
(X) 25 degrees: 38; and
(XI) 30 degrees: 24.
(C) 1.0 Log Credit:
(I) less than or equal to 0.5 degrees:
637;
(II) 1 degree: 610;
(III) 2 degrees: 558;
(IV) 3 degrees: 511;
(V) 5 degrees: 429;
(VI) 7 degrees: 360;
(VII) 10 degrees: 277;
(VIII) 15 degrees: 179;
(IX) 20 degrees: 116;
(X) 25 degrees: 75; and
(XI) 30 degrees: 49.
(D) 1.5 Log Credit:
(I) less than or equal to 0.5 degrees:
956;
(II) 1 degree: 915;
(III) 2 degrees: 838;
(IV) 3 degrees: 767;
(V) 5 degrees: 643;
(VI) 7 degrees: 539;
(VII) 10 degrees: 415;
(VIII) 15 degrees: 268;
(IX) 20 degrees: 174;
(X) 25 degrees: 113; and
(XI) 30 degrees: 73.
(E) 2.0 Log Credit:
(I) less than or equal to 0.5 degrees:
1275;
(II) 1 degree:
1220;
(III) 2 degrees:
1117;
(IV) 3 degrees:
1023;
(V) 5 degrees: 858;
(VI) 7 degrees: 719;
(VII) 10 degrees: 553;
(VIII) 15 degrees: 357;
(IX) 20 degrees: 232;
(X) 25 degrees: 150; and
(XI) 30 degrees: 98.
(F) 2.5 Log Credit:
(I) less than or equal to 0.5 degrees:
1594;
(II) 1 degree:
1525;
(III) 2 degrees:
1396;
(IV) 3 degrees:
1278;
(V) 5 degrees:
1072;
(VI) 7 degrees:
899;
(VII) 10 degrees:
691;
(VIII) 15 degrees:
447;
(IX) 20 degrees:
289;
(X) 25 degrees: 188;
and
(XI) 30 degrees: 122.
(G) 3.0 Log Credit:
(I) less than or equal to 0.5 degrees:
1912;
(II) 1 degree:
1830;
(III) 2 degrees:
1675;
(IV) 3 degrees:
1534;
(V) 5 degrees:
1286;
(VI) 7 degrees:
1079;
(VII) 10 degrees:
830;
(VIII) 15 degrees:
536;
(IX) 20 degrees:
347;
(X) 25 degrees: 226;
and
(XI) 30 degrees: 147.
(F) Systems may use
this equation to determine log credit between the indicated values above: Log
credit = (0.001506 x (1.09116)
Temp) x CT.
(ii) Systems receive the Cryptosporidium
treatment credit listed in this paragraph by meeting the corresponding ozone CT
values for the applicable water temperature, as described in paragraph (a) of
this section. CT values ((MG)(MIN)/L) for Cryptosporidium inactivation by Ozone
listed by the log credit with inactivation listed by water temperature in
degrees Celsius.
(A) 0.25 Log Credit:
(I) less than or equal to 0.5 degrees:
6.0;
(II) 1 degree: 5.8;
(III) 2 degrees: 5.2;
(IV) 3 degrees: 4.8;
(V) 5 degrees: 4.0;
(VI) 7 degrees: 3.3;
(VII) 10 degrees: 2.5;
(VIII) 15 degrees: 1.6;
(IX) 20 degrees: 1.0;
(X) 25 degrees: 0.6; and
(XI) 30 degrees: 0.39.
(B) 0.5 Log Credit:
(I) less than or equal to 0.5 degrees:
12;
(II) 1 degree: 12;
(III) 2 degrees: 10;
(IV) 3 degrees: 9.5;
(V) 5 degrees: 7.9;
(VI) 7 degrees: 6.5;
(VII) 10 degrees: 4.9;
(VIII) 15 degrees: 3.1;
(IX) 20 degrees: 2.0;
(X) 25 degrees: 1.2; and
(XI) 30 degrees: 0.78.
(C) 1.0 Log Credit:
(I) less than or equal to 0.5 degrees:
24;
(II) 1 degree: 23;
(III) 2 degrees: 21;
(IV) 3 degrees: 19;
(V) 5 degrees: 16;
(VI) 7 degrees: 13;
(VII) 10 degrees: 9.9;
(VIII) 15 degrees: 6.2;
(IX) 20 degrees: 3.9;
(X) 25 degrees: 2.5; and
(XI) 30 degrees: 1.6.
(D) 1.5 Log Credit:
(I) less than or equal to 0.5 degrees:
36;
(II) 1 degree: 35;
(III) 2 degrees: 31;
(IV) 3 degrees: 29;
(V) 5 degrees: 24;
(VI) 7 degrees: 20;
(VII) 10 degrees: 15;
(VIII) 15 degrees: 9.3;
(IX) 20 degrees: 5.9;
(X) 25 degrees: 3.7; and
(XI) 30 degrees: 2.4.
(E) 2.0 Log Credit:
(I) less than or equal to 0.5 degrees:
48;
(II) 1 degree: 46;
(III) 2 degrees: 42;
(IV) 3 degrees: 38;
(V) 5 degrees: 32;
(VI) 7 degrees: 26;
(VII) 10 degrees: 20;
(VIII) 15 degrees: 12;
(IX) 20 degrees: 7.8;
(X) 25 degrees: 4.9; and
(XI) 30 degrees: 3.1.
(F) 2.5 Log Credit:
(I) less than or equal to 0.5 degrees:
60;
(II) 1 degree: 58;
(III) 2 degrees: 52;
(IV) 3 degrees: 48;
(V) 5 degrees: 40;
(VI) 7 degrees: 33;
(VII) 10 degrees: 25;
(VIII) 15 degrees: 16;
(IX) 20 degrees: 9.8;
(X) 25 degrees: 6.2; and
(XI) 30 degrees: 3.9.
(G) 3.0 Log Credit:
(I) less than or equal to 0.5 degrees:
72;
(II) 1 degree: 69;
(III) 2 degrees: 63;
(IV) 3 degrees: 57;
(V) 5 degrees: 47;
(VI) 7 degrees: 39;
(VII) 10 degrees: 30;
(VIII) 15 degrees: 19;
(IX) 20 degrees: 12;
(X) 25 degrees: 7.4; and
(XI) 30 degrees: 4.7.
(F) Systems may use this equation to
determine log credit between the indicated values: Log credit = (0.0397 x
(1.09757)Temp) x CT.
(c) Site-specific study. The Director may
approve alternative chlorine dioxide or ozone CT values to those listed in
paragraph (b) above on a site-specific basis. The Director must base this
approval on a site-specific study a system conducts that follows a protocol
approved by the Director.
(d)
Ultraviolet light. Systems receive Cryptosporidium, Giardia lamblia, and virus
treatment credits for ultraviolet (UV) light reactors by achieving the
corresponding UV dose values shown in paragraph (d)(i) of this section. Systems
must validate and monitor UV reactors as described in paragraph (d)(ii) and
(iii) of this section to demonstrate that they are achieving a particular UV
dose value for treatment credit.
(i) UV dose
table. The treatment credits listed in Table 215-5 are for UV light at a
wavelength of 254 nm as produced by a low pressure mercury vapor lamp. To
receive treatment credit for other lamp types, systems must demonstrate an
equivalent germicidal dose through reactor validation testing, as described in
paragraph (d)(ii). The UV dose values in Table 215-5 are applicable only to
post-filter applications of UV in filtered systems.
TABLE 215-5
UV Dose Table for Cryptosporidium,
Giardia lamblia, and Virus Inactivation Credit |
Log credit |
Cryptosporidium UV dose
(mJ/cm2) |
Giardia lamblia UV dose
(mJ/cm2) |
Virus
UV dose
(mJ/cm2) |
0.5 |
1.6 |
1.5 |
39 |
1.0 |
2.5 |
2.1 |
58 |
1.5 |
3.9 |
3.0 |
79 |
2.0 |
5.8 |
5.2 |
100 |
2.5 |
8.5 |
7.7 |
121 |
3.0 |
12 |
11 |
143 |
3.5 |
15 |
15 |
163 |
4.0 |
22 |
22 |
186 |
(ii)
Reactor validation testing. Systems must use UV reactors that have undergone
validation testing to determine the operating conditions under which the
reactor delivers the UV dose required in paragraph (d)(i) of this section
(i.e., validated operating conditions). These operating conditions must include
flow rate, UV intensity as measured by a UV sensor, and UV lamp status.
(A) When determining validated operating
conditions, systems must account for the following factors: UV absorbance of
the water; lamp fouling and aging; measurement uncertainty of on-line sensors;
UV dose distributions arising from the velocity profiles through the reactor;
failure of UV lamps or other critical system components; and inlet and outlet
piping or channel configurations of the UV reactor.
(B) Validation testing must include the
following: Full scale testing of a reactor that conforms uniformly to the UV
reactors used by the system and inactivation of a test microorganism whose dose
response characteristics have been quantified with a low pressure mercury vapor
lamp.
(C) The Director may approve
an alternative approach to validation testing.
(iii) Reactor monitoring.
(A) Systems must monitor their UV reactors to
determine if the reactors are operating within validated conditions, as
determined under paragraph (d)(ii) of this section. This monitoring must
include UV intensity as measured by a UV sensor, flow rate, lamp status, and
other parameters the Director designates based on UV reactor operation. Systems
must verify the calibration of UV sensors and must recalibrate sensors in
accordance with a protocol the Director approves.
(B) To receive treatment credit for UV light,
systems must treat at least 95 percent of the water delivered to the public
during each month by UV reactors operating within validated conditions for the
required UV dose, as described in paragraphs (d)(i) and (ii) of this section.
Systems must demonstrate compliance with this condition by the monitoring
required under paragraph (d)(iii)(A) of this section.
(20) Reporting
requirements.
(a) Systems must report
sampling schedules under R309-215-15(3) and source water monitoring results
under R309-215-15(7) unless they notify the Director that they will not conduct
source water monitoring due to meeting the criteria of
R309-215-15(2)(d).
(b) Filtered
systems must report their Cryptosporidium bin classification as described in
R309-215-15(11).
(c) Systems must
report disinfection profiles and benchmarks to the Director as described in
R309-215-15(9) through R309-215-15(10) prior to making a significant change in
disinfection practice.
(d) Systems
must report to the Director in accordance with the following information on the
following schedule for any microbial toolbox options used to comply with
treatment requirements under R309-215-15(12). Alternatively, the Director may
approve a system to certify operation within required parameters for treatment
credit rather than reporting monthly operational data for toolbox options.
(i) Watershed control program (WCP).
(A) Notice of intention to develop a new or
continue an existing watershed control program no later than two years before
the applicable treatment compliance date in R309-215-15(13).
(B) Watershed control plan no later than one
year before the applicable treatment compliance date in
R309-215-15(13).
(C) Annual
watershed control program status report every 12 months, beginning one year
after the applicable treatment compliance date in R309-215-15(13).
(D) Watershed sanitary survey report:
(I) For community water systems, every three
years beginning three years after the applicable treatment compliance date in
R309-215-15(13).
(II) For
noncommunity water systems, every five years beginning five years after the
applicable treatment compliance date in R309-215-15(13).
(ii) Alternative source/intake
management:
(A) Verification that system has
relocated the intake or adopted the intake withdrawal procedure reflected in
monitoring results No later than the applicable treatment compliance date in
R309-215-15(13).
(iii)
Presedimentation: Monthly verification of the following:
(A) Continuous basin operation
(B) Treatment of 100% of the flow
(C) Continuous addition of a
coagulant
(D) At least 0.5-log mean
reduction of influent turbidity or compliance with alternative Director-
approved performance criteria.
(E)
Monthly reporting within 10 days following the month in which the monitoring
was conducted, beginning on the applicable treatment compliance date in
R309-215-15(13).
(iv)
Two-stage lime softening: Monthly verification of the following:
(A) Chemical addition and hardness
precipitation occurred in two separate and sequential softening stages prior to
filtration.
(B) Both stages treated
100% of the plant flow.
(C) Monthly
reporting within 10 days following the month in which the monitoring was
conducted, beginning on the applicable treatment compliance date in
R309-215-15(13).
(v)
Bank filtration:
(A) Initial demonstration of
the following no later than the applicable treatment compliance date in
R309-215-15(13).
(I) Unconsolidated,
predominantly sandy aquifer
(II)
Setback distance of at least 25 ft. (0.5-log credit) or 50 ft. (1.0-log
credit).
(B) If monthly
average of daily max turbidity is greater than 1 NTU then system must report
result and submit an assessment of the cause. The report is due within 30 days
following the month in which the monitoring was conducted, beginning on the
applicable treatment compliance date in R309-215-15(13).
(vi) Combined filter performance:
(A) Monthly verification of combined filter
effluent (CFE) turbidity levels less than or equal to 0.15 NTU in at least 95
percent of the 4 hour CFE measurements taken each month.
(B) Monthly reporting within 10 days
following the month in which the monitoring was conducted, beginning on the
applicable treatment compliance date in R309-215-15(13).
(vii) Individual filter performance. Monthly
verification of the following:
(A) Individual
filter effluent (IFE) turbidity levels less than or equal to 0.15 NTU in at
least 95 percent of samples each month in each filter.
(B) No individual filter greater than 0.3 NTU
in two consecutive readings 15 minutes apart.
(C) Monthly reporting within 10 days
following the month in which the monitoring was conducted, beginning on the
applicable treatment compliance date in R309-215-15(13).
(viii) Demonstration of performance.
(A) Results from testing following a Director
approved protocol no later than the applicable treatment compliance date in
R309-215-15(13).
(B) As required by
the Director, monthly verification of operation within conditions of Director
approval for demonstration of performance credit within 10 days following the
month in which monitoring was conducted, beginning on the applicable treatment
compliance date in R309-215-15(13).
(ix) Bag filters and cartridge filters.
(A) Demonstration that the following criteria
are met no later than the applicable treatment compliance date in
R309-215-15(13).
(I) Process meets the
definition of bag or cartridge filtration;
(II) Removal efficiency established through
challenge testing that meets criteria in this subpart.
(B) Monthly verification that 100% of plant
flow was filtered within 10 days following the month in which monitoring was
conducted, beginning on the applicable treatment compliance date in
R309-215-15(13).
(x)
Membrane filtration.
(A) Results of
verification testing demonstrating the following no later than the applicable
treatment compliance date in R309-215-15(13).
(I) Removal efficiency established through
challenge testing that meets criteria in this subpart;
(II) Integrity test method and parameters,
including resolution, sensitivity, test frequency, control limits, and
associated baseline.
(B)
Monthly report summarizing the following within 10 days following the month in
which monitoring was conducted, beginning on the applicable treatment
compliance date in R309-215-15(13).
(I) All
direct integrity tests above the control limit;
(II) If applicable, any turbidity or
alternative Director-approved indirect integrity monitoring results triggering
direct integrity testing and the corrective action that was taken.
(xi) Second stage
filtration: Monthly verification that 100% of flow was filtered through both
stages and that first stage was preceded by coagulation step within 10 days
following the month in which monitoring was conducted, beginning on the
applicable treatment compliance date in R309-215-15(13).
(xii) Slow sand filtration (as secondary
filter): Monthly verification that both a slow sand filter and a preceding
separate stage of filtration treated 100% of flow from surface water sources
within 10 days following the month in which monitoring was conducted, beginning
on the applicable treatment compliance date in R309-215-15(13).
(xiii) Chlorine dioxide: Summary of CT values
for each day as described in R309-215-15(19) within 10 days following the month
in which monitoring was conducted, beginning on the applicable treatment
compliance date in R309-215-15(13).
(xiv) Ozone: Summary of CT values for each
day as described in R309-215-15(19) within 10 days following the month in which
monitoring was conducted, beginning on the applicable treatment compliance date
in R309-215-15(13).
(xv) UV:
(A) Validation test results demonstrating
operating conditions that achieve required UV dose no later than the applicable
treatment compliance date in R309-215-15(13).
(B) Monthly report summarizing the percentage
of water entering the distribution system that was not treated by UV reactors
operating within validated conditions for the required dose as specified in
R309-215-15(19) (d) within 10 days following the month in which monitoring was
conducted, beginning on the applicable treatment compliance date in
R309-215-15(13).
(21) Recordkeeping requirements.
(a) Systems must keep results from the
initial round of source water monitoring under R309-215-15(2)(a) and the second
round of source water monitoring under R309-215-15(2)(b) until 3 years after
bin classification under R309-215-15(11) for filtered systems for the
particular round of monitoring.
(b)
Systems must keep any notification to the Director that they will not conduct
source water monitoring due to meeting the criteria of R309-215-15(2)(d) for 3
years.
(c) Systems must keep the
results of treatment monitoring associated with microbial toolbox options under
R309-215-15(15) through R309-215-15(19) for 3 years.
(22) Requirements for Sanitary Surveys
Performed by EPA. Requirements to respond to significant deficiencies
identified in sanitary surveys performed by EPA.
(a) A sanitary survey is an onsite review of
the water source (identifying sources of contamination by using results of
source water assessments where available), facilities, equipment, operation,
maintenance, and monitoring compliance of a PWS to evaluate the adequacy of the
PWS, its sources and operations, and the distribution of safe drinking
water.
(b) For the purposes of this
section, a significant deficiency includes a defect in design, operation, or
maintenance, or a failure or malfunction of the sources, treatment, storage, or
distribution system that EPA determines to be causing, or has the potential for
causing the introduction of contamination into the water delivered to
consumers.
(c) For sanitary surveys
performed by EPA, systems must respond in writing to significant deficiencies
identified in sanitary survey reports no later than 45 days after receipt of
the report, indicating how and on what schedule the system will address
significant deficiencies noted in the survey.
(d) Systems must correct significant
deficiencies identified in sanitary survey reports according to the schedule
approved by EPA, or if there is no approved schedule, according to the schedule
reported under paragraph (c) of this section if such deficiencies are within
the control of the system.